Evidence map›Paper›PMID 36016125›Full record

ArticleVaccines2022

Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses.

Saverio Giuseppe Parisi, Carlo Mengoli, Monica Basso, Ilaria Vicenti, Francesca Gatti, Renzo Scaggiante, Lia Fiaschi, Federica Giammarino, Marco Iannetta, Vincenzo Malagnino and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Saverio Giuseppe ParisiDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Carlo MengoliDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Monica BassoDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Ilaria VicentiDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-4306-2960
Francesca GattiDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Renzo ScaggianteBelluno Hospital, Viale Europa, 22, 32100 Belluno, Italy.
Lia FiaschiDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0003-3599-7384
Federica GiammarinoDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0001-6775-3574
Marco IannettaInfectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0002-6938-8627
Vincenzo MalagninoInfectious Disease Unit, Department of System Medicine, Tor Vergata University and Hospital, Via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0002-6561-5298
Daniela ZagoDepartment of Molecular Medicine, University of Padova, Via Gabelli, 63, 35100 Padova, Italy.
Filippo DragoniDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-8148-9914
Maurizio ZazziDepartment of Medical Biotechnologies, University of Siena, Viale Bracci 16, 53100 Siena, Italy.ORCID 0000-0002-0344-6281
University of Siena · ITUniversity of Padua · ITUniversity of Rome Tor Vergata · ITUniversity of Udine · IT

Funding

European Commission under HORIZON-HLTH-2021-CORONA-01, Project EuCARE grant agreement N. 101046016Ministry of Education, Universities and Research PRIN 2020 LS2 (Genomic epidemiology and phylogenesis of SARS-CoV-2 in Italy: identification and 244 characterization of circulating variants of clinical and public health relevance), Prot. 245 2020XFNCP7_003University of Padua DOR-2019University of Padua DOR-2020
6 · The paper itself

Abstract

We report the time course of neutralizing antibody (NtAb) response, as measured by authentic virus neutralization, in healthcare workers (HCWs) with a mild or asymptomatic SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection diagnosed at the onset of the pandemic, with no reinfection throughout and after a three-dose schedule of the BNT162b2 mRNA vaccine with an overall follow-up of almost two years since infection. Forty-eight HCWs (median age 47 years, all immunocompetent) were evaluated: 29 (60.4%) were asymptomatic. NtAb serum was titrated at eight subsequent time points: T1 and T2 were after natural infection, T3 on the day of the first vaccine dose, T4 on the day of the second dose, T5, T6, and T7 were between the second and third dose, and T8 followed the third dose by a median of 34 days. NtAb titers at all postvaccination time points (T4 to T8) were significantly higher than all those at prevaccination time points (T1 to T3). The highest NtAb increase was following the first vaccine dose while subsequent doses did not further boost NtAb titers. However, the third vaccine dose appeared to revive waning immunity. NtAb levels were positively correlated at most time points suggesting an important role for immunogenetics.

Indexed as

authentic virus neutralizationBNT162b2 mRNA vaccineCOVID-19healthcare workerslong-term follow-upmild or asymptomatic SARS-CoV-2 infectionno reinfectionthird vaccine dose

Identifiers

PMID36016125
PMCPMC9416151
OpenAlexW4289519606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.